Patriot Financial Group Insurance Agency LLC Has $1.15 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Patriot Financial Group Insurance Agency LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 11.8% in the third quarter, Holdings Channel.com reports. The firm owned 13,718 shares of the medical equipment provider’s stock after purchasing an additional 1,445 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Boston Scientific were worth $1,150,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BSX. Cavalier Investments LLC raised its holdings in Boston Scientific by 6.7% during the third quarter. Cavalier Investments LLC now owns 71,841 shares of the medical equipment provider’s stock valued at $6,020,000 after buying an additional 4,485 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Boston Scientific by 1.7% during the third quarter. State of Alaska Department of Revenue now owns 178,166 shares of the medical equipment provider’s stock valued at $14,929,000 after buying an additional 2,955 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Boston Scientific by 123.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 158,538 shares of the medical equipment provider’s stock valued at $13,285,000 after buying an additional 87,470 shares in the last quarter. PFG Investments LLC raised its holdings in Boston Scientific by 3.3% during the third quarter. PFG Investments LLC now owns 7,988 shares of the medical equipment provider’s stock valued at $669,000 after buying an additional 258 shares in the last quarter. Finally, Forsta AP Fonden raised its holdings in Boston Scientific by 19.0% during the third quarter. Forsta AP Fonden now owns 408,900 shares of the medical equipment provider’s stock valued at $34,266,000 after buying an additional 65,300 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BSX. Citigroup raised their target price on Boston Scientific from $92.00 to $98.00 and gave the company a “buy” rating in a report on Thursday, October 24th. BTIG Research raised their target price on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Barclays lifted their price objective on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Thursday, August 22nd. Stifel Nicolaus lifted their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Finally, Robert W. Baird lifted their price objective on Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Three analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Stock Up 0.0 %

NYSE BSX opened at $84.76 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $83.59 and its two-hundred day moving average is $77.98. The company has a market capitalization of $124.35 billion, a price-to-earnings ratio of 71.23, a PEG ratio of 2.87 and a beta of 0.80. Boston Scientific Co. has a 1-year low of $49.56 and a 1-year high of $88.79.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.50 earnings per share. Equities analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the sale, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at $3,061,135.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at $133,046,484.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 316,253 shares of company stock valued at $26,714,298. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.